Investigating the effect of Tdcs on metacognitive therapy in the treatment of major depressed people
- Conditions
- depression.Major depressive disorder, single episode
- Registration Number
- IRCT20190812044515N1
- Lead Sponsor
- Islamic Azad University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Not having a history of participating in a metacognitive psychotherapy program.
Not having a history of epilepsy or convulsions.
Not having a history of shock therapy (ECT).
Having a score above 20 in the Beck depression questionnaire.
Not having acute suicidality to participate in treatment sessions.
Positive safety screening to perform tDCS.
Substance abuse or dependence in the last 6 months (excluding nicotine, with current or past nicotine use)
Psychotic disorders (lifelong) including schizoaffective disorders or depressive episodes with psychotic symptoms (lifelong)
Bipolar disorders (types I and II)
Neurological disorders, such as stroke in the last 2 years, epileptic attacks (for life), epilepsy, dementia, Parkinson's, Huntington's, multiple sclerosis, as well as any other neurological disease that leads to increased intracranial pressure or increased risk of epileptic seizures
Not having a current risk of suicide, based on the researcher's personal assessment
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Depression score. Timepoint: Measurement of depression at the beginning of the study and 10 sessions after the intervention and 30 days after the last visit session. Method of measurement: Beck Depression Questionnaire and Nelen Hoeksma Rumination Questionnaire.
- Secondary Outcome Measures
Name Time Method Rumination. Timepoint: At the beginning of the study and the last visit and 30 days after the last visit. Method of measurement: Nelen Hoeksma Rumination Questionnaire.